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Abstract
Background and Aims: Microarray analysis of RNA expression allows gross examination of pathways operative in
inflammation. We aimed to determine whether genes expressed in whole blood early following initiation of intravenous
corticosteroid treatment can be associated with response.
Methods: From a prospectively accrued cohort of 128 pediatric patients hospitalized for intravenous corticosteroid
treatment of severe UC, we selected for analysis 20 corticosteroid responsive (hospital discharge or PUCAI #45 by day 5)
and 20 corticosteroid resistant patients (need for second line medical therapy or colectomy, or PUCAI .45 by day 5). Total
RNA was extracted from blood samples collected on day 3 of intravenous corticosteroid therapy. The eluted transcriptomes
were quantified on Affymetrix Human Gene 1.0 ST arrays. The data was analysed by the local-pooled error method for
discovery of differential gene expression and false discovery rate correction was applied to adjust for multiple comparisons.
Results: A total of 41 genes differentially expressed between responders and non-responders were detected with statistical
significance. Two of these genes, CEACAM1 and MMP8, possibly inhibited by methylprednisolone through IL8, were both
found to be over-expressed in non-responsive patients. ABCC4 (MRP4) as a member of the multi-drug resistance superfamily
was a novel candidate gene for corticosteroid resistance. The expression pattern of a cluster of 10 genes selected from the
41 significant hits were able to classify the patients with 80% sensitivity and 80% specificity.
Conclusions: Elevated expression of several genes involved in inflammatory pathways was associated with resistance to
intravenous corticosteroid therapy early in the course of treatment. Gene expression profiles may be useful to classify
resistance to intravenous corticosteroids in children with severe UC and assist with clinical management decisions.
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Introduction
Although corticosteroids remain a mainstay of therapy for UC,
a meta-regression of cohort studies in acute severe ulcerative colitis
(UC) showed that 29% of patients fail corticosteroid therapy and
require escalation of medical management or colectomy [1].
Evidence suggests that the dose of the administered corticosteroid
and its bioavailability do not account for response or failure to
therapy [1,2]. Although some case series suggest that prolongation
of corticosteroid therapy is effective in achieving remission in some
refractory cases [3], this approach is associated with increased
toxicity, discomfort, and cost. Several studies have attempted to
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escalation of medical therapy or colectomy early during admission
[1]. In adults, number of daily stools and C-reactive protein have
good predictive ability on the third day of treatment [4,5].
Albumin and bowel luminal width have been also associated with
response to corticosteroid therapy [6]. In children, a predictive
rule based on the Pediatric UC Activity Index (PUCAI) at days
three and five of corticosteroid therapy has been shown to be
superior to the adult scores [7]. A PUCAI value greater than 70
points should prompt initiation of second line therapy as was
recently validated in a prospective cohort of children with severe
UC, yielding positive predictive value (PPV) of 100% and negative
predictive value (NPV) of 79% [8]. Although fecal calprotectin and
pyruvate kinase have a fair predictive role, they do not add
significantly to the clinical PUCAI score [9].
The expression of various proteins and genetic sequence
alterations may contribute to corticosteroid resistance in asthma,
rheumatic disease, and inflammatory bowel disease [10,11,12,13].
For example, high expression levels of Multi Drug Resistance-1
(MDR-1) were found in UC patients who required colectomy [14].
MDR-1 may be involved in corticosteroid resistance by trans-
porting the drug out across the cell membrane. Additionally, in
vitro corticosteroid resistance of T-cells obtained from corticoste-
roid refractory UC patients no longer showed similar findings 3-
months after discharge [15]. No differences in glucocorticoid
receptor expression were observed in leukocytes obtained from
previously corticosteroid responsive and resistant UC patients
currently in remission [16].
RNA microarrays on 6 asthma patients revealed 9 genes,
primarily involved in macrophage activation, to be differentially
expressed between responders and non-responders to corticoste-
roids [17]. A different study by Hakonarson and colleagues
identified over 900 transcripts which were differentially regulated
between corticosteroid responsive and non-responsive asthma
patients [18]. 15 of these transcripts could separate responders
from non-responders with 84% accuracy [19]. No similar studies
exist in UC. The aim of this prospective, multicenter study was to
compare gene expression among children who responded to or
failed intravenous corticosteroid therapy in acute, severe UC.
Methods
Study design
The evaluated patient population was from a nested case-
control study of the outcome of intravenous steroid therapy in ulcerative
colitis individuals (OSCI) study [20]. The OSCI study was a
multicenter, prospective cohort study involving children, 2–18
years of age, hospitalized for intravenous corticosteroid therapy for
acute UC. A diagnosis of UC was established by the presence of
accepted clinical, radiologic, endoscopic and histological criteria
[21]. The research ethics boards of the Hospital for Sick Children,
Mount Sinai Hospital, Izaak Walton Killam Hospital, Children’s
Hospital of Eastern Ontario, and the institutional review boards of
Connecticut Children’s Medical Center, Schneider’s Children’s
Hospital, the Children’s Hospital of Philadelphia, Columbus
Children’s Hospital, and the Hasbro Children’s Hospital approved
this study. Informed, written consent and age-appropriate assent
were obtained from participants and their caregiver, according to
the local policy.
Pre-defined clinical, laboratory and radiographic data were
collected on standardized case report forms at admission, on Day 3
and Day 5 of corticosteroid treatment, upon introduction of
second line medical therapy (infliximab or calcineurin inhibitors)
or colectomy (if applicable), and at hospital discharge. Disease
activity was measured at each visit by the PUCAI [22] which is a
non-invasive, 6-item index, ranging from 0 to 85, intended to
measure disease activity in children with UC. This index was
previously developed and validated by some of the authors using
prospective cohorts and combined mathematical and judgmental
strategies [7,23,24,25]. As part of the OSCI study, in addition to
clinical data, blood was collected for RNA extraction from all
patients on Day 3 of corticosteroid treatment.
Patient selection
The OSCI cohort consisted of 128 children and adolescents
hospitalized for intravenous corticosteroid treatment of acute
severe ulcerative colitis. Of these, 20 corticosteroid-responsive
patients and 20 corticosteroid-refractory patients were selected for
analysis of mRNA expression. All selected patients had been
treated with methylprednisolone. Two batches of 20 patients, each
composed of 10 non-responders and 10 responders, underwent
microarray analysis (Table 1). Selection of subjects among the
eligible non-responders (see below) was random for each batch.
Responders of similar age and matching gender were selected in
order to minimize potential confounding effects. To avoid
selection bias, the inclusion of patients in the two groups was
performed before the RNA assay was carried out and thus
investigators were blinded to the expression results. Response was
defined as no requirement for second line medical intervention or
surgery by discharge and a PUCAI score less than or equal to
45 points by day 5 of therapy. Conversely, patients were
categorized as non-responsive if they required second line medical
Table 1. Basic characteristics of included patients.
Response to IVCS
Yes No p-value
Batch 1 N 1 01 0-
Male/Female 5/5 5/5 1.0000
Age 14.462.2 14.662.2 0.852
Disease Duration (mon.) 9619 12617 0.7372
PUCAI Day 1 77697 5 613 0.6986
PUCAI Day 3 44623 71610 0.0033
PUCAI Day 5 36686 7 613 0.0012
Batch 2 N 1 01 0-
Male/Female 7/3 7/3 1.0000
Age 12.762.6 14.662.4 0.1134
Disease Duration (mon.) 18639 20635 0.8825
PUCAI Day 1 66611 7368 0.1524
PUCAI Day 3 34613 61614 0.0003
PUCAI Day 5 19611 54616 0.0014
Combined N 2 02 0-
Male/Female 12/8 12/8 1.0000
Age 13.662.5 14.662.3 0.1831
Disease Duration (mon.) 14630 16628 0.7778
PUCAI Day 1 71612 74611 0.5217
PUCAI Day 3 39619 66613 ,0.0001
PUCAI Day 5 27613 61616 ,0.0001
N - Number of patients.
IVCS - Intravenous corticosteroids.
doi:10.1371/journal.pone.0013085.t001
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45 on day 5.
Blood sample handling and RNA extraction
Blood samples were collected on Day 3 of intravenous
corticosteroid therapy in PAXgene tubes (PreAnalytiX, QIAGEN)
and stored at 280uC within 24 hours of collection for a period of
less than 1 year. Total RNA was extracted with PAXgene Blood RNA
Kits (QIAGEN) and the obtained elutes were stored at 280uC. The
integrity of all RNA elutes was assessed with Bioanalyzer 2100
(Agilent Technologies) and only samples with RNA Integrity Number
(RIN) greater than 5.5 were used for further analysis [26].
Microarray analysis
Total RNA samples were hybridized to GeneChip Human
Gene 1.0 ST Arrays (Affymetrix), with whole-transcript coverage of
28,869 genes and open reading frames (ORFs). GeneChip Whole
Transcript (WT) Sense Target Labeling Assays with included
quality control GeneChip Hybridization Control Kits (Affymetrix)
were used for sample preparation. The chips were scanned and
raw expression values were obtained with GeneChip Scanner
3000 (Affymetrix). (NCBI Gene Expression Omnibus series record -
GSE21231).
RT-PCR
The reliability of the microarray measurements was assessed
through reverse-transcription real-time polymerase chain reaction
(RT-PCR) measurements of the relative messenger RNA levels of
7 genes. These were selected based on their apparent importance
to IBD disease mechanism. 6 pairs of specific primers were used to
amplify exonic sequences in OLFM4, MMP8, BPI, HP, CD177,
DEFA1 and DEFA3. (Table S1) Due to the high homology
between the sequences of DEFA1 and DEFA3 (99%), GeneChip
Human Gene 1.0 ST Array probes measured the combined
expression of the messenger RNA molecules. Likewise, RT-PCR
primers were chosen to amplify a common segment between the
two genes. The hypoxanthine phosphoribosyltransferase 1
(HPRT1) gene was used as an internal RT-PCR control. 300–
600 gg of total RNA were used with iScrip cDNA Synthesis Kits
(Bio-Rad) to obtain complementary DNA. RT-PCR was performed
with SYBR Green Supermix With ROX (Bio-Rad) and 15–30 gg
of template in a total reaction volume of 25 mL on 96-well plates.
Data analysis
Probesets lacking annotation information were removed from
further analysis. Raw data were background corrected, log
transformed, and quantile normalized using a robust multi-array
average (RMA) algorithm [27]. Within each batch, 21,176 genes
and ORFs were correlated with a binary intravenous-corticosteroid
therapy response variable across all samples using the local-pooled
error(LPE)methodfordetectionofsignificance[28].Genevariance
was estimated by pooling variance estimates of genes with similar
expression from biological replicas across the response groups. Raw
p-values were adjusted for multiple comparisons by the step-up
FDR method [29]. A Monte Carlo simulation was used to estimate
the expected overlap between the results from the two batches [30].
Only the most differentially expressed genes in each batch were
considered for this analysis – 1059 (5% of total) genes with lowest p-
values. Pearson’s chi-squared test was used to compare the expected
to the observed proportion of overlap. All 40 samples were first
normalized separately, then scaled using the R function ‘‘scale’’
(http://www.r-project.org/), and finally pooled together into a
single LPE analysis while controlling for batch effects.
Pharmacogenomic and gene-gene interaction data mining was
accomplished via the Search Tool for Interactions of Chemicals
(STITCH) [31]. Various aspects of molecular interaction were
considered, including: activation, inhibition, binding, phenotypic
similarity, catalysis, and co-expression.
The predictive value of genes correlated significantly with
corticosteroid resistance was assessed by prediction analysis for
microarrays (PAM). This approach utilizes the shrunken centroid
method to identify genes which best characterize each response
group [32]. The procedure was carried out in a 10-fold cross-
validation fashion whereby the complete sample set was randomly
divided into 10 subsets of equal size. Each of the 10 subsets was
consecutively used for validating a classifier which was trained on
the remaining 9 subsets. A classification score for each sample was
determined based on the distance to the nearest shrunken
centroid. The performance of the classifier was then averaged
over the 10 validation events (folds). This cross-validation
approach is very robust and preferred for analyzing fewer than
50 samples due to its high data utilization efficiency [33].
Results
After screening the entire OSCI study cohort, 40 patients were
included according to the predefined criteria as described in
Table 1. Separate LPE analyses of each batch of samples produced
very similar results. When ranked by p-value, an overlap of 341
genes was found between the 5% (1059 genes) of genes with lowest
p-values in both batches. (Figure S1) In other words, the observed
overlap between the results from the two separate analyses was
32.2%. A Monte Carlo simulation indicated that the mean
expected overlap, assuming no correlation between the two
batches, was 52.96360.007 genes with a median of 53 genes
(5%). A chi-squared test showed that there was a very significant
difference between the observed and expected proportion of
overlap (p=4.18610
257).
After correction for multiple testing, 41 genes expressed
differentially between responders and non-responders to therapy
were detected with statistical significance in the pooled analysis.
(Table 2) Some of the most significant genes were Olfactomedin 4
(OLFM4), Matrix Metallopeptidase 8 (MMP8), RAP1 GTPase
Activating Protein (RAP1GAP), 6-phosphofructo-2-kinase (PFKFB2),
Bactericidal Permeability-increasing Protein (BPI), and N-terminal
EF-hand Calcium Binding Protein 1 (NECAB1). The expression of
all significant genes was elevated in patients who had no response to
the administered therapy.
RT-PCR was used to confirm the relative expression obtained
from the microarray experiment. The transcripts of OLFM4,
MMP8, BPI, HP, CD177, DEFA1 and DEFA3 were successfully
measured in real-time using the primers listed in Table S1. We
demonstrated that the RT-PCR and microarray expression values
were highly correlated confirming the validity of the microarray
results. (Figure S2)
Intriguing information on the interconnectivity of some of the
41 significant genes was obtained through network analysis. A
diagrammatic representation of the immediate interactome of
methylprednisolone indicated an inhibitory action on K60, also
known as IL8 (Figure 1) [34]. In turn, IL8 is a known inducer of
CEACAM1 and MMP8 [35,36,37], and it also interacts with BPI,
LCN2 and PPBP [36,38,39,40]. All of these partners of IL8 were
expressed significantly higher in our patients who had no response
to intravenous corticosteroid therapy. A study by Matsuda et al.
showed that IL8 mRNA levels are high during active disease and
low during quiescent disease in UC patients [41]. However, 4%
elevation of IL8 expression levels in our cohort of corticosteroid
Genetics of Steroid Resistance
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p=1).
Finally, the predictive value of the total and various subsets of
the 41 differentially-expressed genes was assessed. (Table 3) Using
all 41 genes, it was possible to classify the 40 tested samples as
belonging to either corticosteroid resistant or responsive patients
with 80% sensitivity and 70% specificity. Subgroups including the
top 40, 35, 30, 25, 20, 15, 10, or 5 of differentially expressed genes
performed similarly as classifiers. While the specificity and
sensitivity decreased with the number of tested genes, neither
value dropped below 60%. Interestingly, the 10 best classifiers of
corticosteroid resistance – RAP1GAP, CD177, ELOVL7, CLIC2,
Table 2. List of genes significantly associated with response to intravenous corticosteroid therapy.
FDR Adjusted P-value Fold Change Gene Symbol Description
Immune System
Associated
,0.0001 1.8 OLFM4 Olfactomedin 4 Yes
,0.0001 1.9 MMP8 Matrix Metallopeptidase 8 (Neutrophil Collagenase) Yes
,0.0001 1.6 RAP1GAP RAP1 GTPase Activating Protein Yes
,0.0001 1.3 PFKFB2 6-phosphofructo-2-kinase -
,0.0001 1.3 BPI Bactericidal Permeability-increasing Protein Yes
,0.0001 1.7 NECAB1 N-terminal EF-hand Calcium Binding Protein 1 -
,0.0001 2.5 CLC Charcot-Leyden Crystal Protein Yes
,0.0001 1.8 TSTA3 Tissue Specific Transplantation Antigen P35B Yes
,0.0001 1.8 GPR84 G Protein-coupled Receptor 84 -
,0.0001 1.3 RPS26P2 Ribosomal Protein S26 Pseudogene 2 -
,0.0001 1.6 HP Haptoglobin Yes
0.0001 1.2 MS4A3 Membrane-spanning 4-domains Yes
0.0001 1.4 SERPINB10 Serpin Peptidase Inhibitor Yes
0.0001 1.4 TDRD9 Tudor Domain Containing 9 -
0.0003 1.3 LCN2 Lipocalin 2 Yes
0.0012 2.0 CD177 CD177 Molecule Yes
0.0012 1.3 RPS26P15 Ribosomal Protein S26 Pseudogene 15 -
0.0013 1.5 GMPR Guanosine Monophosphate Reductase -
0.0017 1.4 CLIC2 Chloride Intracellular Channel 2 -
0.0027 1.5 PROS1 Protein S (Alpha) Yes
0.0063 1.6 TCN1 Transcobalamin I (Vitamin B12 Binding Protein) Yes
0.0072 1.5 CEACAM1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 Yes
0.0073 1.5 HEPACAM2 HEPACAM family member 2 Yes
0.0073 1.5 ATP9A ATPase -
0.0082 1.2 RPS26L 40S Ribosomal Protein S26-like -
0.0128 1.2 DEFA1/DEFA3 Defensin Yes
0.0129 1.3 MBNL3 Muscleblind-like 3 (Drosophila) -
0.0155 1.4 PPBP Pro-platelet Basic Protein Yes
0.0221 1.6 ITGB3 Integrin Yes
0.0244 1.2 CLEC4C C-type Lectin Domain Family 4 Yes
0.0257 1.5 GYPC Glycophorin C (Gerbich blood group) -
0.0257 1.3 CA1 Carbonic Anhydrase I -
0.0284 1.6 ENTPD7 Ectonucleoside Triphosphate Diphosphohydrolase 7 -
0.0284 1.3 VSTM1 V-set and Transmembrane Domain Containing 1 -
0.0361 1.2 SUCNR1 Succinate Receptor 1 -
0.0445 1.6 ELOVL7 ELOVL Family Member 7 -
0.0445 1.2 PSTPIP2 Proline-serine-threonine Phosphatase Interacting Protein 2 -
0.0459 2.2 RNF182 Ring Finger Protein 182 -
0.0459 1.3 ABCC4 ATP-binding Cassette Yes
0.0459 1.8 GPR146 G Protein-coupled Receptor 146 -
Genes with statistically significant association to intravenous corticosteroid therapy response after correction for multiple testing (FDR-adjusted p-values,0.05). The
average fold increase in expression in non-responsive compared to responsive patients, official gene symbol, a short description, and prior evidence of immune
pathway involvement are listed for each gene.
doi:10.1371/journal.pone.0013085.t002
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specific and 80% sensitive. (Table 4) In a completely unbiased
PAM analysis, 9 out of these 10 classifier genes remained within
the 46 best classifiers out of all 21, 176 tested genes. In this
analysis, the most accurate classification was achieved by the use of
662 genes (data not shown) with specificity and sensitivity of 75%.
Discussion
Whole-genome expression analysis of patients receiving intra-
venous corticosteroid revealed 41 genes with expression levels
significantly associated with resistance to the therapy. A substantial
proportion of these genes are known to be involved in the
inflammatory response. Furthermore, mining molecular interac-
tion databases provided a basis for interpreting how these
expression results fit the paradigm of corticosteroid resistance.
Of potential clinical relevance was a set of 10 genes which
classified the treated patients with 80% sensitivity and specificity.
Conceivably, measurement of the expression levels of these genes
could be developed into a practical tool to help identify individuals
who are likely to fail such intravenous corticosteroid therapy and
improve their medication course.
While gene expression changes that occur during treatment may
help elucidate the mechanism of corticosteroid resistance, it is
essential to further investigate the various molecular interactions
alluded to in this study. All genes found to be good classifiers of
corticosteroid resistance must necessarily be validated in a large,
prospective study. Gene expression changes observed on the third
day of therapy are likely to highlight pathways relevant to
corticosteroid metabolism and may be temporal. Conversely,
sampling patients prior to the initiation of therapy would establish
Figure 1. Immediate interactome of methylprednisolone. Point and block arrows indicate activation or inhibition, respectively. Grey lines
represent interactions of undetermined nature, while coloured lines indicate evidence for specific interactions.
doi:10.1371/journal.pone.0013085.g001
Table 3. Class prediction analysis for microarrays using
nearest shrunken centroid method.
Most Significant
Genes (N) Specificity Sensitivity Accuracy
41 80% 70% 75%
40 75% 75% 75%
35 80% 70% 75%
30 70% 70% 70%
25 75% 65% 70%
20 75% 70% 73%
15 70% 60% 65%
10 75% 70% 73%
5 65% 65% 65%
Assessment of the specificity, sensitivity and accuracy for the N most significant
genes (where N equals 41 through 5 in decreasing increments of 5).
Accuracy %=100 * ( True Positives+True Negatives )/Total.
doi:10.1371/journal.pone.0013085.t003
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disease behaviour.
Network analysis revealed that IL-8 function provides a possible
explanation for the observed overexpression of CEACAM1 and
MMP8 in non-responsive patients [35,36,37]. Corticosteroid
resistance could result in reduced inhibition of IL8 by methyl-
prednisolone and thus affect its downstream interactions [34]. IL8
expression was not significantly different between responders and
non-responders in this study despite a previous report of elevated
IL8 mRNA levels in active UC [41]. However, methylpredniso-
lone appears to inhibit IL-8 by preventing its release rather than
by affecting its gene expression [34]. Indeed, this claim is partially
supported by evidence that IL-8 can be stored in Weibel-Palade
bodies for rapid release [42] and its protein levels could remain
briefly stable after changes in its gene expression.
A number of the significant genes identified in this study are of
specific interest due to their prior association with IBD or
pathways implicated in IBD. Olfactomedin 4 (OLFM4) is a gene
encoding a member of the olfactomedin-related protein family.
Selective over-expression of OLFM4 has been reported in inflamed
colonic crypt epithelium in ulcerative colitis patients [43]. The
exact function of the protein, however, is not known. A study by
Zhang et al. indicates that OLFM4 is an anti-apoptotic factor which
attenuates the ability of GRIM19 to facilitate retinoic acid-IFN-b-
mediated apoptosis and the expression of apoptotic genes [44].
Barnich et al. report that GRIM19 interacts with nucleotide
oligomerization domain 2 (NOD2) and is required for the
activation of NF-kB [45]. Interestingly, Liu et al. recently
demonstrated that OLFM4 down-regulates the innate immune
response by influencing NOD1 and NOD2 mediated NF-kB
activation in a mouse model of Helicobacter pylori infection [46].
Other reports implicate OLFM4 expression in tumour growth and,
more specifically, in colon cancer [47,48]. OLFM4 has also been
shown to bind cell-surface lectins and cadherin [49].
Matrix metalloproteinase 8 (MMP8), a collagenase secreted by
neutrophils, was also expressed more highly in patients who were
not responding to intravenous corticosteroids. This proteinase can
degrade type I, II and III collagen and thus affect the extracellular
matrix. A study by Schaaf et al. shows elevated activity of MMP8
in hospitalized patients in the presence of bacteria compared to
controls [50]. Alpha defensin 1 (DEFA1) and 3 (DEFA3) as well as
bactericidal/permeability-increasing protein (BPI) are peptides
secreted by neutrophils in response to bacterial antigens. Elevated
levels of all three proteins have been associated with inflammatory
activity in rheumatoid arthritis [51]. DEFA1 and DEFA3 have also
been implicated in lung epithelial wound repair [52].
HP encodes both the alpha and beta chains of the haptoglobin
tetramer, a protein responsible for the clearance of free plasma
haemoglobin and a mediator of the inflammatory response. HP is
an inducer of IL-6 and plays a role in the balance of Th1 and Th2
cell populations [53,54]. Polymorphisms in this gene have been
associated with Crohn’s disease, disease behaviour and extrain-
testinal manifestations [55]. CD177 is a glycoprotein selectively
expressed by neutrophils and found on their surface. Although its
exact function is not known, it has been identified as a binding
partner of platelet endothelial cell adhesion molecule-1 (PECAM-1)
and it may play a crucial role in the extravasation of neutrophils
into tissues [56]. CD177 expression is increased in individuals with
severe bacterial infections and polycythaemia vera, but not
rheumatoid arthritis [57]. In our study, expression of CD177 was
increased two-fold in patients who did not respond to intravenous
corticosteroid therapy compared to those who did well.
ATP-binding cassette, sub-family C, member 4 (ABCC4)i sa
gene that may directly influence corticosteroid response. ABCC4 is
also known as multi-drug resistance protein 4 (MRP4) and is part
of the same superfamily as MDR1. ABCC4 is an ATP-dependent
transporter and it has been associated with resistance to multiple
drugs. More specifically, it has been shown to actively transport
prostaglandins, methotrexate and steroid- and bile acid-conjugates
[58,59,60].
The results of this study demonstrate that significant gene
expression differences exist between patients who respond to
intravenous corticosteroid therapy and those who are resistant. It
also validates the use of RNA expression analysis as a useful
approach toward improving the understanding of disease
processes and response to medical therapy. Clinically meaningful
tools may also be developed that would allow for the early
stratification of patients into prognostic categories that would
individualize care approaches.
Web Resources
NCBI Gene Expression Omnibus (GEO) - http://www.ncbi.
nlm.nih.gov/geo/
R function ‘‘scale’’ - http://www.r-project.org/
Search Tool for Interactions of Chemicals - http://stitch.embl.de/
Supporting Information
Figure S1 Graphical representation of the analysis used to
compare the results from batch 1 and batch2. The expected
overlap under the null hypothesis was obtained by a Monte Carlo
simulation.
Found at: doi:10.1371/journal.pone.0013085.s001 (1.10 MB
DOC)
Figure S2 Scatterplots illustrate data for genes in each batch as
well as a combined analysis, including R2 values.
Found at: doi:10.1371/journal.pone.0013085.s002 (3.40 MB
DOC)
Table S1 Forward and reverse primers and corresponding
length of RT-PCR products are listed for each of the 7 amplified
genes.
Found at: doi:10.1371/journal.pone.0013085.s003 (0.03 MB
DOC)
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